OverviewSuggest Edit
Tempus Labs is a genomics and data-analytics company. It works with doctors and patients to use genomic data to more effectively choose treatment options based on outcomes from other patients.
| Type | Private | |
| Founded | 2015 | |
| HQ | Chicago, IL, US | Map |
| Website | tempus.com | |
| Employee Ratings | More |
Recent NewsAll News
- Zentalis Pharmaceuticals and Tempus Announce Strategic Collaboration to Advance Research and Development Capabilities
- Tempus Resource by ProSymmetry Now Available on Carahsoft SEWP V and NASPO Contracts
- NeoGenomics and Tempus Join the Access to Comprehensive Genomic Profiling Coalition
- PNC to buy payment gateway provider Tempus Technologies
Key People/Management at Tempus
Eric Lefkofsky
Founder & CEO
Shane Colley
Chief Technology Officer
Joel Dudley
Chief Scientific Officer
Colette Freeman
Chief People Officer
Ryan Fukushima
Chief Operating Officer
Kim Blackwell
Chief Medical Officer
Tempus Office Locations
Tempus has an office in Chicago
Chicago, IL, US (HQ)
600 W Chicago Ave #775
Tempus Financials and Metrics
Summary Metrics
Founding Date | 2015 |
Tempus total Funding | $620 m |
Tempus latest funding size | $100 m |
Time since last funding | a year ago |
Tempus investors | New Enterprise Associates, T. Rowe Price, Baillie Gifford, Revolution Growth, Franklin Templeton, Novo Holdings, Baillie Gifford & Co., Kinship Trust Company |
Tempus's latest funding round in March 2020 was reported to be $100 m. In total, Tempus has raised $620 m. Tempus's latest valuation is reported to be $5 b.
Tempus Revenue
Market valuation | 5.0b |
- Source: Crunchbase News - Mar 2020
Tempus Operating Metrics
Show all operating metricsTempus Acquisitions / Subsidiaries
| Company Name | Date | Deal Size |
|---|---|---|
| AKESOgen | December 11, 2019 |
Tempus Cybersecurity Score
Tempus Online and Social Media Presence
4.07k Twitter followers
Tempus has 4.07k Twitter Followers. The number of followers has increased 1.1% month over month and increased 10.9% quarter over quarter
Tempus's Trends
Twitter Engagement Stats for @tempuslabs
319
Tweets
875
Following
4.1k
Followers
10
Tweets last 30 days
10.5
Avg. likes per Tweet
100%
Tweets with engagement
Tempus News and Updates
February 25, 2021
Zentalis Pharmaceuticals and Tempus Announce Strategic Collaboration to Advance Research and Development Capabilities
Tempus’ platform will be used to further evaluate the DNA damage response pathway of Zentalis’ WEE1 inhibitor, ZN-c3, and potential future candidates Tempus’ platform will be used to further evaluate the DNA damage response pathway of Zentalis’ WEE1 inhibitor, ZN-c3, and potential future candidates
February 23, 2021
Tempus Resource by ProSymmetry Now Available on Carahsoft SEWP V and NASPO Contracts
Powerful Resource Management Solutions Now Available to Government Agencies Powerful Resource Management Solutions Now Available to Government Agencies
February 02, 2021
NeoGenomics and Tempus Join the Access to Comprehensive Genomic Profiling Coalition
Washington, February 2, 2021/ / -- The Access to Comprehensive Genomic Profiling Coalition (ACGP) announced today the addition of NeoGenomics, Inc.read more
January 27, 2021
PNC to buy payment gateway provider Tempus Technologies
PNC Bank N.A. today announced it has reached a definitive agreement to acquire Tempus Technologies, Inc., a leading payment gateway provider that delivers secure and innovative payment-processing solutions for businesses of all sizes.
December 14, 2020
Hummingbird Bioscience Announces Collaboration with Tempus to Harness AI-driven Precision Medicine to Accelerate Clinical Development of HMBD-001 In HER3 Driven Cancers
SINGAPORE, Dec. 14, 2020 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing revolutionary therapies for hard-to-drug targets, today announced a collaboration with Tempus, a leader in artificial intelligence and precision medicine, to...
December 10, 2020
EXCLUSIVE: Billionaire Eric Lefkofsky’s Tempus Raises $200 Million To Bring Personalized Medicine To New Diseases
The Groupon cofounder’s precision medicine company, which uses AI-based diagnostics, has broadened its focus to infectious disease and cardiology in addition to cancer.
Tempus Blogs
June 01, 2021
Tempus Announces Eleven Abstracts Accepted for Presentation at the 2021 American Society of Clinical Oncology Annual Meeting
Tempus, a leader in artificial intelligence and precision medicine, today announced eleven abstracts accepted for presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting taking place virtually from June 4 – 8. “These high impact ASCO presentations from Tempus collaborato…
May 26, 2021
Tempus: 2021 CNBC Disruptor 50
Among the many market revelations to arise from the pandemic, one of the most obvious is that the health-care sector remains, in many ways, under-invested. While Covid highlighted a former No. 1 Disruptor whose technology bet was prescient, mRNA vaccine maker Moderna, Warren Buffett’s references to …
May 26, 2021
Tempus wins breakthrough status for AI-based tool to detect atrial fibrillation
By Meg Bryant March 24, 2021 The U.S. FDA has granted breakthrough device designation to Tempus Inc. for its ECG Analysis Platform. Developed in collaboration with Geisinger, the artificial intelligence (AI)-powered platform helps clinicians identify patients at increased risk of developing atrial f…
May 26, 2021
Tempus unveils prototype cube that talks back to oncologists
Tempus, a Chicago-based health technology company, wants oncologists to talk to the cube. The cube, in this case, is a device called Tempus One that doctors will be able to put in their lab coat pockets and bring with them as they round at hospitals, asking questions about their patients, the geneti…
May 20, 2021
Recommendations for Reporting of Secondary Findings in Clinical Exome and Genome Sequencing
Nature Genetics in Medicine, Tempus-authored — 2021 Update: A Policy Statement of the American College of Medical Genetics and Genomics (ACMG) View the full publication here. Authors: David T. Miller, Kristy Lee, Adam S. Gordon, Laura M. Amendola, Kathy Adelman, Sherri J. Bale, Wendy K. Chung, Micha…
May 20, 2021
Comprehensive Genomic Profiling in Advanced/Metastatic Colorectal Cancer: Number Needed to Test and Budget Impact of Expanded First-line Use
ASCO Annual Meeting 2021, Tempus-authored — Background: A growing number of genomic alterations inform treatment of advanced/metastatic colorectal cancer (mCRC). However, use of comprehensive genomic profiling (CGP) is limited in the first-line (1L) setting. Based on the Tempus xT next-generation se…
Tempus Frequently Asked Questions
When was Tempus founded?
Tempus was founded in 2015.
Who are Tempus key executives?
Tempus's key executives are Eric Lefkofsky, Shane Colley and Joel Dudley.
How many employees does Tempus have?
Tempus has 1,313 employees.
Who are Tempus competitors?
Competitors of Tempus include PathAI, Prognos Health and Genomic Health.
Where is Tempus headquarters?
Tempus headquarters is located at 600 W Chicago Ave #775, Chicago.
Where are Tempus offices?
Tempus has an office in Chicago.
How many offices does Tempus have?
Tempus has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies